Table I.
Association between the clinicopathological characteristics of 97 patients with lung adenocarcinoma and EGFR mutations in the tumors of these patients.
| Characteristic | Patients, n (%) | Wild-type EGFR | Mutated EGFR | P-value |
|---|---|---|---|---|
| Total, n (%) | 97 (100.0) | 53 (54.6) | 44 (45.4) | |
| Gender, n (%) | 0.020 | |||
| Male | 50 (51.5) | 33 (66.0) | 17 (34.0) | |
| Female | 47 (48.5) | 20 (42.6) | 27 (57.4) | |
| Age, n (%) | 0.461 | |||
| <65 years | 38 (39.2) | 19 (50.0) | 19 (50.0) | |
| ≥65 years | 59 (60.8) | 34 (57.6) | 25 (42.4) | |
| Smoking status, n (%) | 0.001 | |||
| No | 46 (47.4) | 17 (37.0) | 29 (63.0) | |
| Yes | 51 (52.6) | 36 (70.6) | 15 (29.4) | |
| CEA level, n (%) | 0.176 | |||
| <5 ng/ml | 50 (51.5) | 24 (48.0) | 26 (52.0) | |
| ≥5 ng/ml | 47 (48.5) | 29 (61.7) | 18 (38.3) | |
| Tumor site, n (%) | 0.199 | |||
| Left upper lobe | 21 (21.6) | 12 (57.1) | 9 (42.9) | |
| Left lower lobe | 13 (13.4) | 6 (46.2) | 7 (53.8) | |
| Right upper lobe | 34 (35.1) | 23 (67.6) | 11 (32.4) | |
| Right middle lobe | 8 (8.2) | 2 (25.0) | 6 (75.0) | |
| Right lower lobe | 21 (21.6) | 10 (47.6) | 11 (52.4) | |
| TNM stage, n (%) | 0.034 | |||
| I | 58 (59.8) | 32 (55.2) | 26 (44.8) | |
| II | 15 (15.5) | 12 (80.0) | 3 (20.0) | |
| III | 24 (24.7) | 9 (37.5) | 15 (62.5) | |
| T factor, n (%) | 0.270 | |||
| 1 | 36 (37.1) | 16 (44.4) | 20 (55.6) | |
| 2 | 49 (50.5) | 29 (59.2) | 20 (40.8) | |
| 3 | 12 (12.4) | 8 (66.7) | 4 (33.3) | |
| N factor, n (%) | 0.231 | |||
| 0 | 64 (66.0) | 38 (59.4) | 26 (40.6) | |
| 1 | 10 (10.3) | 6 (60.0) | 4 (40.0) | |
| 2 | 23 (23.7) | 9 (39.1) | 14 (60.9) | |
| LVI, n (%) | 0.469 | |||
| Negative | 48 (49.5) | 28 (58.3) | 20 (41.7) | |
| Positive | 49 (50.5) | 25 (51.0) | 24 (49.0) | |
| Histopathological score, n (%) | 0.002 | |||
| 2 | 3 (3.1) | 1 (33.3) | 2 (66.7) | |
| 3 | 37 (38.1) | 13 (35.1) | 24 (64.9) | |
| 4 | 39 (40.2) | 26 (66.7) | 13 (33.3) | |
| 5 | 10 (10.3) | 6 (60.0) | 4 (40.0) | |
| 6 | 8 (8.2) | 7 (87.5) | 0 (0.0) | |
| Tumor size median (IQR), mm | 25.0 (18.0–40.0) | 24.0 (16.5–34.8) | 0.334 | |
| SUVmax median (IQR) | 5.7 (3.6–12.8) | 3.8 (2.5–8.9) | 0.034 |
EGFR, epidermal growth factor receptor; CEA, carcinoembryonic antigen; TNM, tumor-node-metastasis; LVI, lymphovascular invasion; SUVmax, maximum standardized uptake value; IQR, interquartile range.